INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

INmune Bio has secured MHRA written alignment from the UK regulatory authority, confirming that pre-marketing authorization Scientific Advice responses support the company's planned 2026 conditional marketing authorization application for CORDStrom in recessive dystrophic epidermolysis bullosa (RDEB). This alignment encompasses CMC (chemistry, manufacturing, and controls), non-clinical, and clinical evidence packages.

The May 12 pre-MAA meeting minutes represent regulatory de-risking for the INMB pipeline, as MHRA alignment typically reduces the probability of major deficiencies or information requests during formal review. This is particularly material for orphan/rare disease programs where patient populations are limited and resubmission windows carry meaningful time and capital costs.

RDEB is a severe genetic blistering disorder with unmet treatment needs; conditional marketing authorization pathways in Europe allow accelerated access based on early efficacy signals where unmet medical need is substantial. The 2026 application timeline suggests phase data readiness within 12–18 months, contingent on trial execution.

Sector implication: This development is modestly positive for rare disease-focused biotech and signals execution confidence, though CORDStrom remains in late-stage development with binary clinical risk. Broader biotech sentiment depends on upcoming trial readouts and cash runway.